Citius Oncology, Inc. (NASDAQ:CTOR) — Stock Price
Citius Oncology, Inc. (NASDAQ:CTOR) is currently trading at $0.74 USD, down 2.06% today. Over the past 52 weeks, shares have ranged between $0.49 and $2.17. This page tracks Citius Oncology, Inc.'s live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see CTOR market cap overview.
Citius Oncology, Inc. (CTOR) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Citius Oncology, Inc.'s daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Citius Oncology, Inc. Income Statement — Revenue, Profit & Earnings by Year
Citius Oncology, Inc.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Research & Development | $6.42 Million | $4.92 Million | $4.24 Million | $6.86 Million |
| SG&A | $17.10 Million | $15.65 Million | $7.88 Million | $2.86 Million |
| Total Operating Expenses | $23.52 Million | $20.57 Million | $12.12 Million | $9.71 Million |
| Operating Income | $-23.52 Million | $-20.57 Million | $-12.12 Million | $-9.71 Million |
| EBITDA | $-23.49 Million | $-20.57 Million | $-12.12 Million | $-4.86 Million |
| EBIT | — | $-20.57 Million | $-12.12 Million | $-4.86 Million |
| Interest Expense | $218.03K | $0.00 | — | — |
| Income Before Tax | $-23.70 Million | $-20.57 Million | $-12.12 Million | $-9.71 Million |
| Income Tax Expense | $1.06 Million | $576.00K | $576.00K | $1.15 Million |
| Net Income | $-24.76 Million | $-21.15 Million | $-12.70 Million | $-10.87 Million |
Citius Oncology, Inc. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Citius Oncology, Inc.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | $100.94 Million | $84.37 Million | $47.73 Million | $42.69 Million |
| Total Current Assets | $27.54 Million | $10.97 Million | $7.73 Million | $2.69 Million |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | — | — | — | — |
| Net Receivables | — | — | — | — |
| Inventory | $22.29 Million | $8.27 Million | $0.00 | — |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | $56.08 Million | $38.23 Million | $22.20 Million | $6.42 Million |
| Total Current Liabilities | $49.49 Million | $32.70 Million | $21.05 Million | $5.85 Million |
| Long-term Debt | $3.80 Million | $3.80 Million | — | — |
| Net Debt | $-124.80K | $3.80 Million | $-26.52K | $-289.18K |
| Total Stockholder Equity | $44.87 Million | $46.14 Million | $25.54 Million | $36.27 Million |
| Retained Earnings | $-64.04 Million | $-39.28 Million | $-18.13 Million | $-5.43 Million |
Citius Oncology, Inc. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Citius Oncology, Inc. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | $-5.49 Million | $126.35K | $-601.30K | $-47.97K |
| Capital Expenditures | $4.00 | $4.00 | $4.00 | $0.00 |
| Free Cash Flow | $-5.49 Million | $126.35K | $-601.30K | $-47.97K |
| Investing Cash Flow | $-5.75 Million | $-5.00 Million | $-1.32 Million | $-67.32 Million |
| Financing Cash Flow | $15.17 Million | $4.87 Million | $1.66 Million | $67.66 Million |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | $8.32 Million | $7.50 Million | $1.97 Million | $0.00 |
| Depreciation | — | — | — | — |
| Change in Cash | $3.92 Million | $-32.63K | $-256.43K | $289.18K |
Citius Oncology, Inc. Earnings History — EPS Actual vs. Analyst Estimates
Track Citius Oncology, Inc.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 18, 2026 | -0.27 | -0.01 | -2600.00% |
| Feb 13, 2026 | -0.06 | -0.02 | -200.00% |
| Dec 23, 2025 | -0.06 | -0.07 | +14.29% |
| Aug 12, 2025 | -0.08 | -0.09 | +11.11% |
| May 14, 2025 | -0.11 | -0.06 | -83.33% |
| Feb 17, 2025 | -0.09 | -0.06 | -55.17% |
| Dec 30, 2024 | -0.31 | -0.08 | -282.38% |
| Aug 28, 2024 | 0.04 | — | — |